<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="50440">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02125929</url>
  </required_header>
  <id_info>
    <org_study_id>PUMCHGS2013</org_study_id>
    <secondary_id>ENRLO</secondary_id>
    <nct_id>NCT02125929</nct_id>
  </id_info>
  <brief_title>Comparative Study of Robotic, Laparoscopic and Open Surgery for Enucleation of Benign Pancreatic Neoplasms</brief_title>
  <official_title>Comparative Study of the Efficacy and Safety Outcomes of Robotic, Laparoscopic and Open Surgery for Enucleation of Benign Pancreatic Neuroendocrine Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking Union Medical College Hospital</source>
  <oversight_info>
    <authority>China: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the efficacy and safety of robotic, laparoscopic and open surgery for
      enucleation of benign pancreatic neuroendocrine tumors
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study was prospective and retrospective, non-randomized study included patients with
      benign pancreatic neoplasms. The robotic arm consecutively includes patients underwent
      robotic enucleation surgery and expected number in this arm is 50. The laparoscopic and open
      surgery arms retrospectively include case from the year 2004. The number of patients for
      laparoscopic and open surgery arms are 50 and 100, respectively.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2014</start_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Pancreatic fistula rate</measure>
    <time_frame>up to 30 days</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality rate</measure>
    <time_frame>up to 30 days</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Intra-operative bleeding volume</measure>
    <time_frame>intra operative</time_frame>
    <safety_issue>Yes</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Operation Time</measure>
    <time_frame>Intra operative</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Conversion rate to open surgery</measure>
    <time_frame>Intra operative</time_frame>
    <safety_issue>No</safety_issue>
    <description>Only applied to the robotic surgery arm and laparoscopic arm</description>
  </other_outcome>
  <other_outcome>
    <measure>Quality of life and pain scores</measure>
    <time_frame>up to 30 days</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Delayed gastric emptying rate</measure>
    <time_frame>up to 30 days</time_frame>
    <safety_issue>Yes</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Intra-abdominal bleeding rate</measure>
    <time_frame>up to 30 days</time_frame>
    <safety_issue>Yes</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Postoperative infection rate</measure>
    <time_frame>up to 30 days</time_frame>
    <safety_issue>Yes</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Hospital stay time</measure>
    <time_frame>up to 30 days</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Pancreatic Neuroendocrine Tumors</condition>
  <arm_group>
    <arm_group_label>robotic arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>robotic surgery for enucleation benign Pancreatic Neuroendocrine Tumors Case number = 50</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Laparoscopic surgery</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>laparoscopic surgery for enucleation benign Pancreatic Neuroendocrine Tumors Case number = 50</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Open surgery</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Open surgery for enucleation benign Pancreatic Neuroendocrine Tumors Case number = 100</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Robotic surgery</intervention_name>
    <description>Robotic surgery: enucleation benign Pancreatic Neuroendocrine Tumors</description>
    <arm_group_label>robotic arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Laparoscopic surgery</intervention_name>
    <description>Laparoscopic surgery: enucleation benign Pancreatic Neuroendocrine Tumors</description>
    <arm_group_label>Laparoscopic surgery</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Open surgery</intervention_name>
    <description>Open surgery: enucleation benign Pancreatic Neuroendocrine Tumors</description>
    <arm_group_label>Open surgery</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18-80 years old

          -  Body Mass Index&lt;30

          -  Preoperative diagnosis of resectable benign Pancreatic Neuroendocrine Tumors

          -  Tumor type: Non-functional pancreatic endocrine tumours and insulinomas

          -  largest diameter &lt; 4cm

          -  Preoperative CT showed no evidence that tumor was connected with main pancreatic duct

        Exclusion Criteria:

          -  Severe cardio/pulmonary complications

          -  Other pancreatic diseases, including pancreatitis and pancreatic cancer

          -  Multiple pancreatic neuroendocrine tumors

          -  Distant metastasis
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yupei Zhao, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking Union Medical College Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wenming Wu, MD</last_name>
    <email>doctorwuu@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of General Surgery, Peking Union medical school hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wenming Wu, MD</last_name>
      <email>doctorwuu@126.com</email>
    </contact>
    <investigator>
      <last_name>Yupei Zhao, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 28, 2014</lastchanged_date>
  <firstreceived_date>April 26, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
    <mesh_term>Neuroendocrine Tumors</mesh_term>
    <mesh_term>Adenoma, Islet Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
